Official HCP Site



For your patients with scalp psoriasis

In a Phase III clinical study of moderate–severity scalp psoriasis, significantly more patients treated with SORILUX Foam achieved treatment success compared with vehicle foam.1

Learn more.

For your patients with body psoriasis

In two 8-week, Phase III studies, SORILUX Foam was shown to be safe and effective for treating mild to moderate plaque psoriasis of the body.2,3

Learn more.

Give your patients the only single-agent calcipotriene therapy available in an elegant foam formulation

SORILUX Foam delivers effective, steroid–free treatment for scalp and body psoriasis.

  • Penetrates the skin barrier to deliver the molecule into the epidermis and dermis4
  • Aqueous-based emulsion that is easy to apply to both hair-bearing and non–hair-bearing areas5
  • Absorbs quickly without greasiness or residue4,5
  • No ethanol, preservatives, or fragrances
  • The contribution to efficacy of individual components of the vehicle has not been established

Most insured, eligible patients will pay $0 for a SORILUX Foam prescription.

References: 1. Feldman SR, Eastman WJ, Brundage T, Mills M. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol. 2013;12(3):300-306. 2. Feldman SR, Matheson R, Bruce S, et al; U0267-301 & 302 Study Investigators. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012;13(4):261-271. 3. SORILUX Foam [package insert]. Greenville, NC: Mayne Pharma; 2019. 4. Data on file. Greenville, NC; Mayne Pharma LLC. 5. Weiss S, Wyres M, Brundage T. A novel foam vehicle is consistently preferred by patients for dermatologic conditions. J Am Acad Dermatol. 2011;64(2):AB50.


SORILUX Foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years and older.

For more information, please see full Prescribing Information and Patient Information Leaflet

Important Safety Information

  • SORILUX Foam should not be used by patients with known hypercalcemia
  • The propellant in SORILUX Foam is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application
  • Transient, rapidly reversible elevation of serum calcium has occurred with use of calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored
  • SORILUX Foam is not for oral, ophthalmic, or intravaginal use
  • Adverse reactions reported in ≥1% of subjects treated with SORILUX Foam and at a higher incidence than subjects treated with vehicle were application site erythema (2%) and application site pain (3%). The incidence of these adverse reactions was similar between the body and scalp

Medical Information & Adverse Drug Events Reporting

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or the FDA at 1-800-FDA-1088 or